Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Status:
Terminated
Trial end date:
2017-05-22
Target enrollment:
Participant gender:
Summary
This phase 1-2 trial studies the side effects and best dose of cetuximab-IRDye 800CW when
used with intraoperative imaging, to determine the utility of cetuximab-IRDye 800CW to
identify and assess pancreatic cancer in patients undergoing surgery to remove the tumor.
Cetuximab-IRDye 800CW may help doctors better identify cancer in the operating room by making
the cancer visible when viewed through a fluorescent imaging system.